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Abstract
The aim of this review is to provide a brief overview of some current approaches regarding diagnostics, pathologic features, 
treatment, and genetics of prostate carcinoma (PCa). Prostate carcinoma is the most common visceral tumor and the second 
most common cancer-related cause of death in males. Clinical outcomes for patients with localized prostate cancer are excellent, 
but despite advances in prostate cancer treatments, castrate-resistant prostate cancer and metastatic prostate cancer patients 
have a poor prognosis. Advanced large-scale genomic studies revealed a large number of genetic alterations in prostate cancer. 
The meaning of these alterations needs to be validated in the specific prostate cancer molecular subtype context. Along these 
lines, there is a critical need for establishing genetically engineered mouse models, which would include speckle type BTB/POZ 
protein and isocitrate Dehydrogenase (NADP (+)) 1 mutant, as well as androgen receptor neuroendocrine subtypes of prostate 
cancer. Another urgent need is developing highly metastatic prostate cancer models, as only up to 17% of available models dis-
play bone metastases and exhibit a less typical neuroendocrine prostate cancer or sarcomatoid carcinoma. Moreover, androgen 
deprivation and relapse should be mimicked in the genetically engineered mouse models, as androgen independence may yield 
a better model for metastatic castrate-resistant prostate cancer. The development of such refined animal models should be guid-
ed by comparative genomics of primary versus corresponding metastatic tumors. Such an approach will have the potential to 
illuminate the key genetic events associated with specific molecular prostate cancer subsets and indicate directions for effective 
therapy. Conclusion. Despite excellent results in the treatment of localized prostatic carcinoma, castrate-resistant prostate can-
cer and metastatic prostate cancer have a poor prognosis. Advanced large-scale genomic studies revealed a large number of ge-
netic alterations in PCa. Experimental models of prostate carcinoma in genetically modified mice could provide new data about 
the genetic changes in such cancers and help in developing better animal models for treatment resistant prostate carcinomas.
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Introduction
Prostate cancer (PCa) is the most common vis-
ceral tumor in males, with more than 1.1 million 
newly diagnosed cases each year worldwide. It is 
the second most common cancer-related cause of 
death in males due to malignant tumors, with ap-
proximately 300,000 deaths per year (1). It usually 
appears in persons older than 50 years. These days, 
most PCa are routinely diagnosed in asymptomat-
ic patients by a simple and easily performed proce-
dure that includes prostate-specific antigen (PSA) 
measurement and needle core biopsy. Such an 
approach enables adequate and timely treatment, 
leading to a good prognosis. In the pathogenesis 
of prostate cancer, various exogenous and endog-
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enous factors are involved. The second one include 
inherited and acquired genetic and epigenetic 
changes. Understanding role of these factors con-
cerning the occurrence and progression of PCa 
to a lethal outcome in some patients has a crucial 
translational impact on the detection, diagnosis, 
and prognosis of this frequently occurring cancer. 
Specifically, predicting men at risk for developing 
a lethal PCa vs. an indolent one is extremely im-
portant, but currently unmet clinical need (2, 3). 
This review will provide a brief overview of some 
current approaches regarding diagnostics, patho-
logic features, treatment, and genetics of PCa.
Diagnostics of Prostate Cancer
The suspicion of prostate cancer arises from digi-
torectal examination (DRE) and/or rising of the 
PSA levels. Most PCas are located in the peripheral 
zone and may be detected by DRE in conjunction 
with PSA value when the volume is >0.2 mL (4, 5). 
The use of PSA as a serum marker has revolution-
ized PCa diagnosis (4). This marker may be elevat-
ed in benign prostatic hypertrophy, prostatitis, and 
other non-malignant conditions. As an indepen-
dent variable, PSA is a better predictor of cancer 
than either DRE or transrectal ultrasound (TRUS) 
(5). PSA is a continuous parameter, with higher 
levels indicating a greater likelihood of PCa. Cur-
rently, PSA is a gold-standard marker also used 
for assessing PCa risk and biochemical recurrence 
(BRE) (6). With respect to PCa, the PSA sensitiv-
ity and specificity of 60% and 79%, respectively, 
makes it the organ-specific marker but cannot be 
considered as a tumor-specific marker (7). One 
should be aware of high false-positive rates in in-
dolent, low-risk localized PCa that may lead to 
overtreatment of PCa patients. On the other hand, 
many clinically significant PCa remain undetected 
until presented in the advanced stage (8). 
The need for a better marker has been recog-
nized and addressed timely. As a result, there are 
many tests currently available. They may be ap-
plied before and after taking the biopsy. Blood-
based risk assessment tests that reduce unneces-
sary biopsies by ~ 40% are the Prostate Health In-
dex (PHI) and 4Kscore. The first test relies on total 
PSA, free PSA, and precursor PSA, while the sec-
ond one relies on total PSA, free PSA, intact PSA, 
and human kallikrein2 (7). In the modern era, 
genomic, epigenetic, and proteomic-based bio-
markers are available to augment PSA and reduce 
unnecessary biopsies. They are all expected to im-
prove diagnostics, staging, and monitoring. Final-
ly, they can contribute to the knowledge needed to 
understand the basis of tumor aggressiveness and 
guide therapy decisions. Novel biomarkers are not 
necessarily restricted to proteins in a specific tis-
sue or the blood. Instead, there may be other types 
of molecules (micro RNA (mi-RNA), for example) 
present in various biological specimens (9). 
Urine-based noninvasive tests are useful for 
deciding whom to biopsy (SelectMDx, EndoDX 
Prostate IntelliScore) while the combination of 
urine- and tissue-based markers are useful for de-
ciding whom to rebiopsy (SelectMDx, EndoDX 
Prostate IntelliScore, Progensa PCA3, The Michi-
gan Prostate Score (MiPS), ConfirmMDx). The 
positive aspect of these tests should be considered 
for reducing the number of unnecessary biopsies 
and for improving a discrimination between clini-
cally significant and indolent PCa. They are very 
useful for avoiding overdiagnosis (7). SelectMDx 
measures Homeobox C6 (HOXC) and Distal-
Less Homeobox 1 (DLX1) mRNA in urine. In 
contrast, EndoDX Prostate IntelliScore measures 
Prostate Cancer-Associated 3 (PCA3), ETS tran-
scription factor ERG and SAM Pointed Domain 
Containing ETS Transcription Factor (SPDEF) 
mRNA in urinary exosomes (7). Progensa PCA3 
is a urine-based assay that measures the level of 
prostate-specific long noncoding PCA3 and PSA 
transcripts. The PCA3/PSA mRNA ratio is used 
to aid in repeated biopsy decision-making (10). 
The Michigan Prostate Score evaluates chime-
ric transcript Transmembrane Serine Protease 2 
– TMPRSS2:ERG and PCA3 mRNA in urine and 
normalizes it with serum PSA (11). ConfirmMDx, 
considering that non-tumors cells adjacent to the 
cancer are epigenetically changed, detects changes 
in DNA methylation of Glutathione S-Transferase 
pi1 (GSTP1), Ras Association Domain Family 
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Member 1 (RASSF1), and Adenomatous Polyposis 
Coli (APC) genes in histopathologically negative 
biopsy tissue (7, 12).
Currently, there are four commercially avail-
able tests for assessing PCa behavior and guiding 
therapy decisions for localized disease. ProMark 
quantifies eight protein markers in biopsy tissue of 
Gleason score 3+3 and 3+4. It is useful for predict-
ing the risk of PCa aggressive behavior and help-
ful in the situation when the therapist must decide 
between active surveillance and active treatment 
(13). OncotypeDX Genomic Prostate Score deter-
mines mRNA levels of 17 genes in biopsy tissue 
of Gleason score 3+3 and 3+4 to predict aggres-
siveness, adverse pathology, and biochemical re-
currence (7). Decipher measures RNA expression 
of 22 genes in biopsy or prostatectomy specimens. 
The test results predict a 5-year risk for clinical 
metastases and 10-year PCa-specific mortality risk 
from both specimens. It adds to the accuracy for 
predicting the existence of a high-grade PCa from 
the biopsy and is also helpful for making decisions 
related to therapy protocol (radiation therapy tim-
ing and hormone deprivation therapy) (14). Pro-
laris determines RNA expression of 31 cell cycle 
progression genes and 15 housekeeping genes in 
biopsy or prostatectomy specimens to predict can-
cer aggressiveness, PCa-specific mortality, and 
therapy decision-making (active surveillance or 
definitive treatment) (15).
Multiparametric-magnetic resonance imaging 
(mp-MRI) has shown promising results in diag-
nosis, localization, risk stratification, and clinically 
significant prostate cancer (16). Mp-MRI includes 
high-resolution T2-weighted imaging (T2WI) 
and at least two functional MRI techniques (17). 
Suspicious lesions in mp-MRI are graded using 
the Prostate-Imaging Reporting and Data Scoring 
System (PIRADS) version 2 (18). PI-RADS™ v2 as-
sessment uses a 5-point scale based on the likeli-
hood that a combination of mp-MRI findings cor-
relates with the presence of a clinically significant 
cancer for each lesion in the prostate gland. There 
are five assessment categories (18) ranging from 
PI-RADS 1 – very low probability (clinically sig-
nificant cancer is highly unlikely to be present) to 
PI-RADS 5 – very high probability (clinically sig-
nificant cancer is highly likely to be present). Three 
methods based on MRI guidance are available for 
performing the targeted prostate biopsy: a) Cog-
nitive fusion, in which the ultrasound operator 
positions the biopsy needle in the prostate area 
where the prior MRI demonstrated a lesion; b) Di-
rect MRI-guided biopsy, performed within an MRI 
tube; and c) Software coregistration of stored MRI 
with real-time ultrasound, using a fusion device 
(19). Correlation with radical prostatectomy (RP) 
specimens shows that mp-MRI has good sensitivity 
for the detection and localization of the Internation-
al Society of Urological Pathology (ISUP) grade > 2 
cancers but is less sensitive in identifying PCas ISUP 
grade 1 (20). MRI-TBx (MRI-targeted biopsies) sig-
nificantly out-performs systematic biopsy to detect 
ISUP grade > 2 in the repeat-biopsy setting. In biop-
sy-naïve patients, the difference appears less marked 
and not significant in all series, but it remains in fa-
vor of MRI-TBx in most studies (20). 
Although DRE, TRUS, and MR are beneficial, 
the definitive diagnosis depends on histopatho-
logical verification of adenocarcinoma in prostate 
biopsy cores (20).
Pathology
On gross examination, prostate carcinoma is a 
gritty and firm, gray-yellow, poorly circumscribed 
tumor, which can be more easily felt than seen. 
Accurate identification of prostate cancer by gross 
inspection is possible in only 63% of cases, with 
a 19% false-positive rate (21). These days grading 
is performed according to the World Health Or-
ganization (WHO) 2016 recommendations based 
on the original Gleason grading system. Defined 
initially by Donald Gleason and published in the 
1960s and 1970s (22, 23), the score is based on 
prostate adenocarcinoma histological patterns. It 
has been refined over the years and is nowadays 
the most widely used grading system (23). Grad-
ing should include primary and secondary Glea-
son grade, Gleason score as well as grade group 
that is determined on the basis of Gleason grades. 
Different architectural patterns have been as-
74
Acta Medica Academica 2021;50(1):71-87
signed a number from 1 to 5 (from well to poorly 
differentiated). Gleason score is a sum of the two 
most prevalent Gleason grades and ranges from 2 
to 10. However, in practice, only scores from 6 to 
10 are usually used. There were some other incon-
sistencies in the Gleason system that led to some 
modifications and a grade group proposal that has 
been subsequently validated on a large number 
of patients (24). Today, grade groups from 1 to 5 
and Gleason grading, are used according to WHO 
2016 classification (23, 24).
Microscopically, prostate carcinoma is usu-
ally composed of small glands. However, medium 
to large papillary or cribriform glands or solid 
growth, as well as single cells, can be found. The cy-
toplasm is usually finely granular but may be clear/
foamy due to intracellular lipid accumulation. Blu-
ish luminal mucin and/or crystalloids can be seen 
in the lumina of neoplastic glands and peritumoral 
clefting around some glands (23, 25-27). There are 
nuclear enlargement, hyperchromasia, and promi-
nent nucleoli. Mitotic figures are quite uncommon 
except in high-grade tumors (21, 25). However, 
diagnosis is based on at least three criteria, some 
of which are mentioned earlier. These criteria are 
favoring but not diagnostic of adenocarcinoma. 
Some features are associated with false-positive 
diagnoses, such as atrophic cytoplasm, atypical 
glands associated with inflammation, adenosis, 
and many others (21, 25, 26). Certain features are 
confirmative and diagnostic, including perineural 
invasion, mucinous fibroplasia, and glomeruloid 
structures (21, 25, 26). Diagnosis is occasionally 
difficult and for that reason some immunohisto-
chemical methods should be used such as antibod-
ies to p63, PSA, ERG, high-molecular weight cy-
tokeratin, alpha-methyl CoA racemase (AMACR) 
and others.
Treatment of PCa
Approaches for managing localized PCa include 
active surveillance, brachytherapy, external beam 
radiation, radical prostatectomy and androgen de-
privation therapy (28). Radical prostatectomy (as 
a surgical treatment of PCa) is the gold standard 
because hormone therapy and chemotherapy are 
usually not curative. Not all cancer cells can be 
eradicated consistently by radiation or other phys-
ical forms of energy, even if the tumor is localized 
within the prostate capsule. Moreover, if the pros-
tate gland remains in situ, new prostate cancers can 
develop in the residual prostatic epithelium. There 
are four different approaches to radical prosta-
tectomy: open perineal, open retropubic, manual 
laparoscopic, and robot-assisted laparoscopic ap-
proaches (29). Radical prostatectomy is indicated 
for the treatment (with curative intent) of patients 
in good condition with localized PCa whose life 
expectancy exceeds ten years (30).
While clinical outcomes for patients with lo-
calized PCa are excellent, metastatic PCa patients 
have a poor prognosis. The treatment of choice for 
metastatic PCa is androgen deprivation therapy 
(ADT) and, if ADT fails, cytotoxic chemotherapy. 
Phase III clinical trials investigating their combi-
nation are in progress (31). Hormone-sensitive 
PCa, even under low-androgen conditions, prog-
ress to lethal, castration-resistant PCa (CRPC). 
Therapy for castration-resistant PCa are androgen 
receptor (AR) signaling inhibitors and, in case of 
failure, AR-directed therapy, chemotherapy, Radi-
um-223, poly (ADP-ribose) polymerase (PARP)-
inhibitors (if harboring BRCA1, BRCA2, or ATM 
alterations) and immunotherapy are available (31-
33). There are indications that androgen inhibition 
enhances cell sensitivity to PARP-inhibitors, and 
several clinical trials based on their combination 
are currently underway (33). Since the adverse 
effect of ADT is a decrease in bone mineral den-
sity, a combination of ADT and bisphosphonates 
is recommended but only in documented osteo-
porosis or androgen-independent prostate cancer 
with bone metastasis (34). Despite advances in 
CRPC treatments, it remains lethal. New strate-
gies that would achieve long-term disease remis-
sions are needed. Potentially targetable molecular 
targets may be p300/CBP, fibroblast growth fac-
tor (FGF), Wnt family member 5A (WNT5A)/
receptor tyrosine kinase-like orphan receptor 1 
(ROR1), tyrosine kinase ACK1, and STEAP1 (Six-
transmembrane epithelial antigen of prostate-1). 
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Bipolar androgen therapy that combines a perma-
nent ADT with high doses of testosterone applied 
monthly showed promising outcomes, which were 
even better when combined with checkpoint im-
munotherapy was applied (31).
Genetics of Prostate Carcinoma
Prostate cancer has an extraordinarily complex 
genetic makeup containing mutations, DNA copy-
number changes, rearrangements, and gene fu-
sions (2, 3, 35). These aberrations are associated 
with extensive changes in the epigenetic landscape 
(36). Multiple studies have shown a genetic com-
ponent to the etiology of prostate cancer, which 
has been reviewed elsewhere (2, 3, 35-39). Epide-
miological studies have shown that a family his-
tory of prostate cancer may significantly increase 
PCa occurrence risk (39). Twin studies have indi-
cated a substantial heritability of prostate cancer 
(35). Large-scale genome-wide association stud-
ies (GWASs) have identified many prostate can-
cer susceptibility loci (3, 35), including 63 novel 
risk-associated single-nucleotide polymorphisms 
(SNPs), among which four SNPs (rs111599055, 
rs11859370, rs2788524, rs56366063) were shown 
to be clinically significant (40). 
Several large-scale genomic studies in both pri-
mary malignant prostate tumors and metastatic 
castration-resistant prostate cancer (mCRPC) 
have identified recurrent DNA copy number 
changes, mutations, rearrangements, and gene 
fusions such as familial mutations in Homeobox 
B13 (HOXB13) and DNA repair genes, including 
BRCA2, ATM, Checkpoint Kinase 2 (CHEK2), 
BRCA1, DNA Repair Protein RAD51 Homolog 4 
(RAD51D), and Partner and Localizer of BRCA2 
(PALB2) (3, 35). It is known that germline muta-
tions in BRCA genes are associated with increased 
risk for prostate cancer and a more aggressive phe-
notype and worse outcomes (3, 35).
Primary prostate tumors and mCRPC exhibit 
markedly increased genome-wide copy number 
alterations (35, 38). On the other hand, somat-
ic point mutations are less common in prostate 
cancer than in most other solid tumors (41). The 
whole-exome sequencing analysis applied to 333 
tumors revealed only 0.94 mutations per megabase 
(mut/Mb), corresponding to 19 non-synonymous 
mutations per tumor genome (median; 13–25, 
25th, and 75th percentiles respectively) (41). As 
recently published, this contrasts with, for exam-
ple, numbers related to small cell lung carcinomas 
of which 40% (N=122) was shown to contain a 
high mutation burden, defined as 10 mut/Mb (42). 
Prior exome sequencing of 112 prostate cancers 
identified 12 recurrently mutated genes through 
focused assessment of point mutations and short 
insertions and deletions (43). Moreover, differenc-
es in prostate cancer incidence and outcome have 
been observed in men from different racial/ethnic 
groups, with men of African descent having the 
highest incidence and mortality rates, which may 
partially be attributed to genetic factors (44). The 
heritability factor is crucial when mutations are 
present in DNA-repair genes (45). 
Another important factor relates to the activity 
of the androgen pathway, as the signaling pathway 
mediated by AR plays a central role in the prostate 
gland’s development and function. Studies using 
conventional approaches and next-generation se-
quencing (NGS) have revealed that a majority of 
primary and metastatic prostate cancers harbors 
genomic alterations in the androgen signaling path-
way, including AR amplification/mutations, gain of 
AR nuclear receptor coactivator 1/2 (NCOA1/2), 
and loss of AR nuclear receptor corepressor 1/2 
(NCOR1/2) which contributes to castration resis-
tance (46). In addition, AR genomic structural re-
arrangements are present in one-third of mCRPC 
tumors, resulting in aberrant expression of diverse 
AR variant species lacking the ligand-binding do-
main and resulting in persistent activation of AR 
signaling, such as AR variant 7 (AR-V7), which 
appears to drive disease progression (47, 48).
Based on the previously mentioned study (41), 
it seems that a high proportion of all prostate can-
cers (74%) can be assigned to one of seven molecu-
lar classes based on oncogenic fusions: 1) ERG, 2) 
ETV1, 3) ETV4, or 4) FLI1 (46, 8, 4, and 1% respec-
tively), or mutations in 5) SPOP, 6) FOXA1, or 7) 
IDH1 mutations (11, 3, and 1% respectively) (41).
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Changes in the Number of Chromosomes and 
Copy Number Variations of Select Chromosomal 
Regions
Changes in Chromosomal Number There are few 
reports on chromosome number changes associ-
ated with prostate cancer progression (49-51). 
Braun et al. were explored 428 PCa, and PCa re-
lated specimens (186 localized, 75 lymph node 
metastasized, 125 lymph node metastases, 42 hor-
mone-refractory distant metastases) and observed 
a significant increase in aneuploidy with advanced 
tumor stage (49). An increased expression of the 
mitotic marker Phosphorylated Histone H3 – 
PHH3 was significantly associated with aneuploi-
dy and higher pT stage (49). Copy number gains 
were most commonly present on chromosomes X 
(26.6%), 21 (22.8%), Y (20.7%), 14 (19.2%), and 
8 (17.7%), while the losses of chromosomes 20 
(11.0%), 10 (4.1%), and 6 (4.0%) accounted for 
the most frequent monosomies. However, while 
overall ploidy status and PHH3 expression in pri-
mary tumors indicate advanced disease, a fluores-
cence in situ hybridization (FISH) – based test for 
distinct alterations did not seem to be beneficial 
for diagnostic or prognostic purposes (49). Celep 
et al. observed numerical aberrations in 41% of 
19 analyzed prostate cancer cases (50). The most 
frequent aberration was a loss of chromosome 9 
that was detected in 12 (63%) samples, followed 
by monosomic chromosomes 8, 7, and 17, which 
were present in 11 (58%), 9 (47%), and 6 (32%) 
tumors, respectively. The highest rate for trisomy 
was observed for chromosome 7 (three tumors, 
16%) (50). There were no significant aberrations 
in benign prostate hyperplasia (BPH) samples. 
Visakorpi et al. studied 23 prostate cancer and 10 
BPH specimens by FISH using pericentromeric 
repeat-specific probes for 10 chromosomes (51). 
All BPH specimens were diploid, without appar-
ent chromosomal aberrations, as assessed by flow 
cytometry and FISH. In prostate carcinoma, flow 
cytometry and FISH revealed abnormal DNA 
content in 35% and 74% of tumors, respectively. 
Aberrant copy number of chromosomes 7, X, and 
8 were found in approximately 40% of cases. Sim-
ple chromosome losses were uncommon. Still, in 
DNA tetraploid tumors, relative losses (trisomy or 
disomy) of several chromosomes were often found, 
with chromosome Y being most commonly affect-
ed, suggesting prostate cancer progression through 
tetraploidization, followed by losses of selected 
chromosomes. The most recent data have convinc-
ingly shown that, over a median follow-up of 15.3 
years, increasing tumor aneuploidy strongly associ-
ates with an increased risk of lethal prostate cancer. 
When comparing the biological behavior of tumors 
with the same Gleason score, 23% of patients with 
five or more altered chromosome arms in their 
tumors had fivefold higher odds of lethal disease 
compared with those without aneuploidy (52).
Copy Number Alterations Copy number al-
terations (CNAs) are gains or losses in genetic 
material that affect a larger fraction of the ge-
nome. These alterations are found in nearly 90% 
of prostate cancers (2). Somatic tumor CNA bur-
den (TCB) and genome-wide CNA patterns were 
shown to be associated with biochemical recur-
rence and metastasis in primary prostate cancer, 
especially in low and intermediate-risk prostate 
cancer patients (Gleason scores of 7 and less) (53). 
Tumor CNA burden as a continuous variable was 
also shown to be significantly associated with 
prostate cancer-specific death (53) in conservative 
treatment cohort, independent of Gleason sum 
score and Cancer of the prostate risk assessment 
(CAPRA) score (53). Copy number alterations 
(gains and losses) have an integral role in both the 
activation of oncogenes and inactivation of tumor 
suppressor genes. For example, the most common 
loss of 8p (the minimal region of deletion: 8p21.3-
p21.2 harboring NK3 Homeobox 1 (NKX3-1)) 
was found in 304 of 546 (55.7%) and 105 of 116 
(90.5%) cases of localized and advanced prostate 
carcinoma, respectively. Other common deletions 
in primary tumors were also on chromosomes 
13q (13q13-q31.1; loss of RB transcriptional co-
repressor 1 (RB1)), 5q11.2-q23.3, 17p13.3-p11.2, 
10q23.2-q26.12, 18q. On the other hand, the gain 
of chromosome 8q was identified in 114 of 546 
(20.9%) and 97 of 116 (83.6%) primary and ad-
vanced cases, respectively (54). In metastatic tu-
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mors, hundreds of aberrations can be found. This 
phenomenon may reflect increasing genomic in-
stability, which relates to disease progression. 
Recent genetic studies revealed that mCRPCs 
with neuroendocrine (NE) features commonly are 
RB1 and TP53 deficient and display attenuated AR 
signaling compared with non-metastatic CRPC 
(35, 51). On the other hand, castration-resistant 
metastatic tumors often show amplification of 
chromosomes X, 7, 8q, and 9q and include genes 
from the androgen receptor pathway and the MYC 
oncogene. Numerous studies have demonstrated 
an increase of MYC copy number in up to 50% of 
prostate cancers (55). Overexpression of Myc in 
mice resulted in prostatic intraepithelial neopla-
sia (PIN) with progression to invasive carcinoma 
(56). Besides, Myc functions as a driver in the met-
astatic Pten/Trp53-deficient Rapid CaP genetically 
engineered mouse models (GEMM) (57), in which 
Myc activation in combination with phosphatase 
and tensin homolog (PTEN) loss drives genomic 
instability and contributes to the occurrence of 
metastatic disease (58, 59). 
It is challenging to detect CNAs in the sample 
obtained by prostatic needle core biopsy. There-
fore, it was proposed that their identification 
should be performed in circulating and dissemi-
nated tumor cells from blood and bone marrow, 
respectively (3). However, the most recent data did 
not confirm circulating prostate cancer cells in the 
blood and bone marrow of patients with a local-
ized prostate tumor (60).
Structural Rearrangements
Improper repair of double-stranded DNA breaks 
can result in both intra- and inter-chromosome re-
arrangements. The most common prostate cancer 
genomic alterations are translocations involving 
androgen-regulated promoters and the ETS fam-
ily of transcription factors, such as ERG and the 
E twenty-six family of transcription factors (ETV) 
genes (61). In the previously mentioned study 
(41), 53% of tumors were found to have ETS-fam-
ily gene fusions (ERG, ETV1, ETV4, and FLI1). 
A recurrent gene fusion of the 5’ untranslated 
region of the androgen-responsive TMPRSS2 to 
ERG (TMPRSS2:ERG) was the first translocation 
discovered by Tomlins and collaborators (62). This 
type of fusion is present in ~50% of localized pros-
tate cancers (35). This chimera expression confers 
an increased risk of disease relapse after treatment 
for clinically localized prostate cancer due to the 
growth-promoting activity of the ERG oncogene 
under the control of the regulatory elements of 
TMPRSS2 gene. The presence of TMPRSS2:ERG 
chimera varies concerning ethnicity and is more 
prevalent (~50%) in Caucasians than in African‐
Americans (31.3%) and Japanese patients (15.9%) 
(63). Several other rearrangements have been de-
scribed in prostate cancer, including ESRP1:CRAF, 
the ETS family, and RAF kinase gene fusions (64). 
ERG-associated rearrangement has been associ-
ated with 10q, 17p, and 3p14 deletions (65). On 
the other hand, those tumors without ERG rear-
rangement exhibit 6q and 16q deletion and 7q am-
plification (65). The whole-genome sequencing of 
primary prostate tumors T2c or greater, and Glea-
son grade 7 or higher obtained from seven patients 
showed a median of 90 structural rearrangements 
(range 43–213) per tumor genome, highlighting 
the prevalence and complexity of these changes 
as well as the importance of chromatin structure. 
Further, in the tumors with TMPRSS2:ERG, rear-
rangement breakpoints were enriched near open 
chromatin, androgen receptor, and ERG DNA 
binding sites (66).
Single Nucleotide Polymorphisms and Point 
Mutations
The mutation rate is a crucial factor in determining 
a somatic cells risk of malignant transformation. 
Kan et al. have shown a low number of mutations 
(0.33 per Mb) in 58 analyzed prostate cancers, as-
sociated with a high number of TMPRSS2–ERG 
gene fusion transcripts, which were present in 75% 
of samples (67). Still, even with such a low muta-
tion rate, there are crucial and clinically important 
genes for occurrence, development, and biologi-
cal behavior of prostate carcinoma. It is thought 
that, on average, less than 20 mutations are likely 
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to affect protein stability or function. For example, 
in Kan’s research, only three genes (TP53, speckle 
type BTB/POZ protein (SPOP), and A-kinase an-
choring protein 9 (AKAP9) were shown to have 
a significant prevalence of protein-altering muta-
tions (q-score ≥1.0) (67). 
On the other hand, there are genes whose 
SNPs gained interest concerning PCa occurrence 
and progression. Some of these polymorphisms 
were thoroughly analyzed. However, in the RNA-
SEL (HPC1) gene (1q25.3), elaC Ribonuclease Z 
2 (ELAC2 or HPC2) (17p12), and macrophage 
scavenger receptor 1 (MSR1) (8p22), none of the 
polymorphisms analyzed was shown to be a strong 
prognostic/predictive and independent factor for 
prostate cancer (68, 69) (Table 1).
However, there is no doubt that prostate can-
cer is a polygenetic disease that is highly depen-
dent on SNP–based genetic risk score (GRS). The 
first reported study assessing the association of a 
polygenic risk score derived from well-established 
risk-associated SNPs with patient age at PCa di-
agnosis was published in 2019 (70). The indepen-
dent PCa risk-associated SNPs discovered through 
GWAS were defined through three standard cri-
teria (70), which allowed for the profiling of 110 
PCa risk-associated SNPs. The paper was shown 
a significant association of GRS with patient age 
at PCa diagnosis, especially when combined with 
family history. The highest risk allele frequency 
(RAF) value (0.93) was shown for rs12480328. 
This polymorphism is located in the intron of the 
activity-dependent neuroprotector homeobox 
gene (ADNP). So far, there are no data related to 
the importance of this gene in PCa. 
Several GWAS have revealed the SNPs 
rs2292884 (missense mutation in melanophilin, 
MLPH; 2q37.3) and rs902774 in the noncoding 
region 12q13 (38). A large meta-analysis based on 
78 PCa GWAS risk associations within 85 distinct 
genomic regions was recently published (71). Al-
though numerous data have been published, the 
final confirmation of some SNPs as bona fide prog-
nostic markers is yet to come. For example, the 
polymorphism rs2735839 in the PSA coding gene, 
kallikrein-related peptidase 3, (KLK3), was crucial 
when estimating the occurrence and biological be-
havior of PCas in several populations (72, 73). A 
recently published meta-analysis, including 35,838 
patients and 36,369 control subjects, did not find 











Innate immunity, part of the 
interferon-regulated 2-5A system
Alvarez-Cubero et al., 2016 (68);
Liu et al., 2018 (69);





17p12; 25 exons tRNA biosynthesis; interacts with 
activated Smad Family Member 2 
(SMAD2)
Alvarez-Cubero et al., 2016 (68);




Mutation 8p22; 12 exons The isoforms type 1 and type 2 
mediate the endocytosis of modified 
low density lipoproteins (LDLs).The 
isoform 3 inhibits the function of 
isoforms type 1 and type 2
Alvarez-Cubero et al., 2016 (68);
Liu et al., 2018 (69);
Wallis et al., 2015 (3)
SPOP (TEF2; 
BTBD32)
Mutation 17q21.33; 16 exons Modulation of the transcriptional 
repression activity of death-
associated protein 6
Clark et al., 2020 (75); An et al., 








Mutation 2q34; 2 exons Oxidative decarboxylation Kang et al., 2009 (80); Ghiam et 
al., 2012 (81); Dang et al., 2009 
(82); Waitkus et al., 2018 (83)
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an association between rs2735839 and the risk for 
PCa. It was, however, shown that there is a strong 
association between rs1058205 (T>C) and the de-
creased risk of PCa (74).
SPOP SPOP has been found to be mutated in 
prostate cancer in a range from 4.4% to 28.6% of 
cases (75). The inability of the mutant SPOP to in-
duce degradation of full-length AR and inhibit AR-
mediated gene transcription is of great importance 
for prostate cancer pathogenesis (76). However, 
the mutant SPOP (SPOP-F133V) was not con-
firmed as a strong prostate cancerogenesis driver 
in a transgenic mouse with prostate-specific con-
ditional expression of the mutant allele, although it 
was associated with strong PI3K/mTOR signaling. 
However, when mice expressing mutant SPOP in 
a conditional Pten heterozygous background (Pb-
Cre; PtenL/+; R26F133V) was generated, a highly 
penetrant phenotype with focal areas of high-
grade prostatic intraepithelial neoplasia (HG-PIN) 
by six months of age was observed (77). The vali-
dation model presented by human SPOP mutant 
organoids revealed that SPOP mutations associate 
with specific changes, including genomic deletions 
at 5q21, 6q15, and 2q21 (77). On the other hand, 
SPOP mutant prostate cancers were shown to be 
exclusively negative for ETS rearrangement. All 
these facts point to the SPOP mutation-positive 
prostate cancers as a distinct molecular subtype. 
There is a high similarity in mRNA, copy-number, 
and methylation profiles in tumors with FOXA1 
mutations and those with SPOP mutations.
Forkhead Box A1 – FOX1A Zhou et al. were 
recently shown that FOXA1 mRNA is consistent-
ly the most abundant mRNA in prostate tumors, 
ranking in the 95th percentile in 492 of 497 pros-
tate tumors deposited in TCGA (78). By analyzing 
3086 primary and metastatic prostate cancers, Ad-
ams et al. (79) were shown FOXA1-related aberra-
tions in 11.4 % of samples. Among them, 3% were 
genomic amplifications, while 8.4% of tumors 
had somatic point mutations. Less than 1% of tu-
mors were carrying both types of changes. Over 
50% of FOXA1 mutations in the cited study were 
mapped to a specific hotspot in Wing2 of the fork-
head (FKHD) DNA-binding domain, mainly be-
tween H247 and F266. These mutations were more 
prevalent in primary locoregional cases. Trunca-
tion mutations with consequential loss of the C-
terminal transactivating domain were presented 
with 20% (79). Some functional consequences of 
these mutations will be explained later.
Isocitrate Dehydrogenase-1 (IDH1) In 2009, 
Kang et al. were shown the presence of the IDH1 
point mutations (R132H and R132C) in only two 
out of 75 analyzed prostate cancers (80). This find-
ing was confirmed three years later; identical IDH1 
point mutations in codon 132 were discovered 
in two out of 158 analyzed prostate cancers (81). 
IDH1 is a cytoplasmic metabolic enzyme needed 
for oxidative decarboxylation of isocitrate to 2-ox-
oglutarate (α-ketoglutarate). When one allele is 
mutated, abnormally high 2-hydroxyglutarate (2-
HG) production associated with an extensive re-
shape of cellular epigenome occurs (82). Targeting 
altered IDH1 in various tumors, including select 
prostate cancer patients, would be of the most sig-
nificant interest (83). Although mutations in IDH1 
are the most common in gliomas, the first mutant 
IDH1 blocking drug (ivosidenib) was approved by 
the FDA in 2019 for treating adults with relapsed 
or refractory acute myeloid leukemia (AML) with 
an IDH1 mutation. Whether PCa may be targeted 
in a similar way remains to be seen.
General Epigenetic Landscape in Prostate 
Cancer and Micro-RNAs
Deregulation of genes controlling epigenetic pro-
cesses involved in DNA modification (e.g., meth-
ylation and hydroxymethylation), histone modifi-
cation, or nucleosome remodeling has been rec-
ognized as a tumorigenesis driver in many cancer 
types, including prostate cancer. Genomic DNA 
can be methylated by canonical DNA methyltrans-
ferase (DNMT) consisting of DNMT1, DNMT3A, 
and DNMT3B at the C-5 position of the cytosine 
within CpG dinucleotides, which are present in 
CpG islands (CGIs). There is app. 50,000 experi-
mentally supported CGIs (eCGIs) in the human 
genome (84). Their length varies between 200 bps 
and 3.6 kbps. DNA methylation in normal cells 
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ensures that gene expression and gene silencing 
are adequately regulated. Aberrant level of DNA 
methylation is a part of disturbing epigenetics 
found in cancers. In the malignantly transformed 
cell, DNA is commonly hypermethylated in pro-
moter regions of tumor suppressor genes, leading 
to decreased activity. Notwithstanding this fact, 
cancer is a disease of global hypomethylation, 
which is commonly present in non-coding regions 
of DNA. In prostate cancer, hypomethylation of 
noncoding long interspersed nuclear elements 
(LINE-1), which constitutes approximately 17% 
of the human genome, was shown in 1999 (85). 
As recently reviewed by Lam et al., the methyla-
tion rate of certain genes in prostate cancer may 
be considered a valid prognostic parameter for 
certain disease aspects (86). With respect to meth-
ylation, among all explored genes so far, none was 
shown to be undoubtedly predictive when all stud-
ies were taken into consideration (86). The reasons 
for these findings include diversity in sample type, 
cohort size, clinical endpoints examined, methyla-
tion profiling methodologies, analytical approach, 
and clinicopathological factors adjusted for in 
multivariate analyses. The methylation status of 
the PITX2 (paired-like homeodomain transcrip-
tion factor 2)gene (4q25) seems to be highly con-
clusive for predicting biochemical recurrence-free 
survival in prostate cancer patients after radical 
prostatectomy (RP) (training cohort: hazard ra-
tio (HR) = 1.83 (95 % CI 1.07–3.11), P=0.027; 
validation cohort: HR=2.56 (95 % CI 1.44–4.54), 
P=0.001 (87). 
The only commercially available epigenetic 
test, ConfirmMDx, is made for diagnostic pur-
poses. It is set up to produce binary results based 
on the methylation status of three genes: APC, 
RASSF1, and GSTP1, to detect cancer in histologi-
cally negative biopsies. Methylation-positive test 
result profiles men who are at increased risk of 
harboring occult (high-grade) cancer. Methylation 
negative samples spare the patient from unneces-
sary repeat biopsy due to the high accuracy of the 
test (negative predictive value (NPV) between 90% 
and 96%) (88, 89).
Previously described transcription factor 
FOXA1 is a “pioneer factor” that can bind to 
DNA in those segments where the chromatin is 
compacted. The role of FOXA1 is to contribute to 
increased accessibility of these regions for other 
transcription factors to bind (90). Specifically, in 
prostate tissue, FOXA1 plays a crucial role in AR-
mediated gene regulation and signaling. AR chro-
matin binding is dependent on FOXA1 (91). The 
molecular basis of this process is not simple. Gao 
et al. were recently shown that lysine-specific his-
tone demethylase 1A (LSD1) may regulate FOXA1 
chromatin binding through directly demethylat-
ing its lysine 270, in vitro (91). The complexity of 
this process should be kept in mind when con-
sidering LSD1 inhibitors for treating tumors with 
mutated or highly expressed FOXO1. In prostate 
cancer, this may be problematic because the loss 
of FOXA1 can result in transdifferentiation from 
AR/FOXA1-driven adenocarcinoma to neuroen-
docrine prostate cancer (NEPC). This aggressive 
subtype is AR-ligand independent (92, 93).
Micro-RNA and Prostate Cancer Mi-RNAs are 
a class of small noncoding RNAs (22-25 nucleo-
tides long) that bind to messenger RNA (mRNA). 
Consequently, they negatively influence protein 
expression through cleavage of specific target 
mRNAs or inhibition of their translation (94). 
Thus, a specific mi-RNA’s functional role depends 
on the role of the specific mRNA, which is a miR-
NA binding partner (95). If specific mi-RNA tar-
gets mRNA originating from a tumor suppressor 
gene, then it has a strong potential to act as onco-
genic mi-RNA (96). If, on the other hand, miRNA 
targets mRNA originating from an oncogene, it 
may be considered a tumor-suppressive molecule 
in a specific tissue. Mi-RNAs are highly promis-
cuous molecules as one miRNA may bind to and 
control numerous target mRNAs simultaneously. 
Currently, 2654 mature human miRNA sequenc-
es are known (97). Many miRNAs are located in 
genetically unstable sites where they are prone to 
deletion or rearrangement, which occur in can-
cer (98). Accordingly, the miRNAs located in the 
chromosomal regions of deletion show the lowest 
expression level.
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In contrast, the miRNAs located in the regions 
of amplifications show the highest expression lev-
els (99). Many miRNA genes are located next to 
CpG islands, where they may be prone to epigene-
tic silencing through methylation. In prostate can-
cer, this miRNA silencing mechanism was shown 
in 2014 through analysis of 74 formalin-fixed, 
paraffin-embedded (FFPE) clinical specimens: 
24 normal prostate samples and 50 PCa samples 
from radical prostatectomies (100). Methylation 
occurred in 0%, 5%, and 13% of cancers for miR-
18b, miR-148a, and miR-450a/542-3p, respec-
tively, while no methylation was present in control 
samples. The same research study has shown that 
low levels of miR-132 correlated with a higher rate 
of metastatic events, lymph node invasion, and 
shorter recurrence-free time (Table 2). There was 
a negative correlation of miR-132 expression lev-
els with the overall Gleason score and tumor stage 
(100). Two years later, Qu et al. demonstrated that 
decreased miR-132 levels in prostate cancer cells 
positively regulate the Warburg effect through in-
hibiting solute carrier family 2 member 1 SLC2A1/
GLUT1 expression (101).
In 2007, Porkka et al. published a seminal pa-
per describing miRNA expression in 4 BPHs, 
5 untreated prostate carcinomas, and four hor-
mone-refractory prostate carcinomas (99). Their 
work has shown a unique profile of 51 differen-
tially expressed miRNAs (PCa vs. BPH: 37 and 
14 miRNAs downregulated and upregulated, 
respectively). Among these miRNAs, 22 and 8 
were decreased and increased in all carcinoma 
samples, respectively, whereas 15 and 6 of them 
were downregulated and upregulated, respectively, 
only in the hormone-refractory carcinomas com-
pared with BPH samples. These early data pointed 
out on mi-RNAs as unique molecules, which are 
mechanistically involved in prostate cancer devel-
opment. They were confirmed in recent studies. 
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Table 2. Some miRNAs with confirmed clinical value associated with Prostate Carcinoma 
miRNA Locus Clinical Significance Mode of Action References
miR-132 17p13.3 Downregulated in human 
PCa tissues; miR-adverse 
correlation with Gleason 
score
In vitro: inhibition of TGF-β 
(transforming growth factor-β)-induced 
EMT)
Formosa et al., 2013 (100); 
Qu et al., 2016 (101); Liu et 
al., 2016 (102)
miRNA -146a 5q33.3 Downregulated in 
androgen-independent 
prostate cancer (AIPC) 
tissue, suppressive role
Regulation of ROCK/Caspase 3 
signaling pathway
Xu et al, 2015 (103)
miR-141 12p13.31 Associated with increased 
risk of biochemical PC 
recurrence.
In vitro: Suppression of prostate 
cancer stem cells and metastasis by 
targeting a cohort of pro-metastasis 
genes, including Enhancer of Zeste 
Homologue 2 (EZH2)
Richardsen et al., 2019 
(105);  Liu et al., 2017 (106) 
miR-375-3p 2q35 Prediction of time to 
progression in mCRPC 
patients treated with 
docetaxel or abiraterone
Predicted targets: CCND2, MAP3K2, 
MXI1, PAFAH1B1, YOD1, ZFYVE26
Zedan et al., 2020 (107); 
Ciszkowicz et al., 2020 
(108) 
miR-331-3p 12q22 High expression is 
associated with advanced 
PC stage and distant 
metastases
Suppressive role through targeting 
NACC1, ERBB-2 expression and 
androgen receptor signaling. 
Oncogenic role through stimulation of 
epithelial-to-mesenchimal transition 
(EMT)
Epis et al., 2009 (111); 
Morita et al, 2018 (112);






13q31.3 Oncogenic role in majority 
of prostate cancer models.
Specific targeting of SERTAD3 with 
miR-92a;enhancement of migration 
and invasion in vitro, attributed to the 
induction of integrin β-1
Zhang et al 2020 (114); 
Zhou et al 2016 (115)
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For example, the difference between androgen-
dependent- (ADPC) and androgen-independent 
prostate cancer (AIPC) tissues was shown to be 
dependent on miR-146a and its influence on 
Rho-associated coiled-coil containing protein ki-
nase 1 (ROCK1) kinase (102, 103). The presence 
of miRNAs in plasma of PCa patients was for the 
first time described in 2008 (104). The potential 
discriminatory miRNA was shown to be miR-141, 
which had the most significant differential expres-
sion and could detect individuals with cancer with 
60% sensitivity at 100% specificity (104). In PCa 
tissues (N=535), expression of miR-141 in the epi-
thelial part of the tumor significantly correlates to 
Gleason score ≥8 (P=0.040) and large tumor size 
(≥20 mm, P = 0.025). In contrast, its overall expres-
sion (defined as both epithelial and stromal expres-
sion) strongly relates to Gleason grade (P=0.001) 
(105). It was recently shown that plasma levels of 
miR-141-3p and miR-375-3p might predict time 
to progression in mCRPC patients treated with 
docetaxel or abiraterone; their high baseline levels 
were significantly associated with shorter overall 
survival (OS) in the abiraterone and in docetaxel 
treated patients (106-108).
There are also efforts to explore the clinical 
value of mi-RNAs in the urine. A novel logistic re-
gression model based on five urine miRNAs (miR-
151a-5p, miR-204-5p, miR-222-3p, miR-23b-3p, 
and miR-331-3p) and PSA were recently shown 
as a strong predictor for biochemical recurrence 
(109). 
The crosstalk between miRNAs and molecules 
belonging to various signaling pathways may be 
established through strong networks containing 
transcription factors and various protein kinases. 
Erb-b2 receptor tyrosine kinase 2, ERBB2 (Her-2/
neu), is a tyrosine kinase receptor that is overex-
pressed in abiraterone-resistant prostate cancer. It 
was recently shown to be included in the activa-
tion of the PI3K/AKT signaling and stabilization 
of AR protein. Accordingly, it was hypothesized 
that combination therapy with abiraterone and 
ERBB2 antagonists might be effective for treating 
the subset of CRPC with increased ERBB2 activ-
ity (110). In 2009, miR-331-3p expression was 
shown to be reduced in prostate tumors relative to 
normal adjacent tissue and is inversely correlated 
with ERBB2 mRNA expression (111). Thus, in this 
specific scenario, miR-331-3p may be considered 
to be a suppressive molecule (112, 113). At least 
ten different miRNAs have been found to be in-
volved in apoptosis. In many cases, their way of 
acting follows a cascade pattern. Up-regulation 
of the miR-17-92 cluster leads to overexpression 
of miR-20a, which subsequently targets E2F1-3 
transcription factors (114-116). Then, depending 
on the cell cycle phase, reduced E2F1-3 results 
either in cellular proliferation or reduced apop-
tosis via TP53 and caspase activity, thus creating 
an auto-regulatory feedback loop as E2F1-3 con-
trols miR-20a expression. MiR-21 also contrib-
utes to apoptosis through the mechanism, which 
includes TP53 and is preserved in various malig-
nant tumors (117). In prostate cancer specifically, 
miR-21 acts as an oncogenic factor, as it targets 
both PDCD4 (programmed cell death 4) (118) 
and PTEN mRNA (119). Numerous biological 
processes can be significantly affected by mi-RNA 
molecules. For example, MiR-15a and miR-16-1 
are down-regulated in most prostate tumors (120).
Conclusions
Advanced large-scale genomic studies revealed a 
large number of genetic alterations in PCa. The 
meaning of these alterations needs to be validated 
in the context of the specific PCa molecular sub-
type. Along these lines, there is a critical need for 
establishing GEMMs, which would include SPOP 
and IDH1 mutants and AR−NE− subtypes of 
PCa. Another urgent need is the development of 
highly metastatic PCa models, as less than 20% of 
available models display bone metastases and ex-
hibit a less typical NEPC or sarcomatoid pathol-
ogy. Moreover, androgen deprivation and relapse 
should be mimicked in the GEMMs models, as 
androgen independence may yield a better model 
for metastatic CRPC. The development of such re-
fined animal models should be guided by compar-
ative genomics of primary PCa and corresponding 
metastases. Such an approach will potentially illu-
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minate the critical genetic events associated with 
specific molecular Pca subsets and indicate direc-
tions for effective therapy.
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